In today's Pharmaceutical Executive Daily, Senate Democrats press major pharmaceutical companies for transparency on the ...

By Michael Erman and Mariam Sunny March 19 (Reuters) - The U.S. government has begun engaging pharmaceutical companies as it works to build consensus around legislation to write President Donald Trump ...

The global pharmaceutical market is valued at $1.7 trillion, offering lucrative investment prospects. Choosing the right pharmaceutical stocks involves evaluating consistent revenue growth and robust ...

The company's pipeline features almost 40 programs in late-stage clinical testing. These clinical trials are testing new drug candidates and seeking additional approvals for drugs such as Tremfya.

Amgen and Abbott are ditching horseshoe crab blood for synthetic alternatives — a win for a 450-million-year-old species ...

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two ...

Europe’s pharmaceutical industry needs to make sure it doesn't become yesterday's news. Its biopharmaceutical innovation capacity has been gradually declining for decades, and the rapid ascent of ...